Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description adds substantial behavioral context beyond the readOnlyHint annotations, including data sources (SEC EDGAR/XBRL, FAERS), handling of off-calendar fiscal years, sorting by primary metric, and return of paired data plus pipeworx:// citation URIs. No contradictions with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is concise yet dense, packing trigger phrases, usage rules, data-source details, sorting behavior, and return format into a structured paragraph. Every sentence serves a purpose, and the critical 'ALWAYS PREFER' guidance is front-loaded.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description fully explains what the tool returns (paired data + citation URIs), covers both entity types, mentions edge cases (off-calendar fiscal years), and clarifies the sort order. It is complete for a tool with this complexity and parameter scope.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema already provides 100% coverage of both parameters, so the baseline for value-add is 3. The description further enriches meaning by explaining what data each type pulls (company: 10-K revenue, net income, cash, long-term debt; drug: adverse-event counts, FDA approvals, trials) and clarifies the values array semantics with examples, justifying a 4.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description explicitly states the tool performs side-by-side comparison of 2–5 companies or drugs in a single parallel call, with specific trigger phrases ('X vs Y', 'which is bigger'). It distinguishes itself from sequential single-pack lookups, which are the clear alternative.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives a direct usage directive: 'ALWAYS PREFER over sequential single-pack lookups when comparing entities,' and specifies the contexts for company vs. drug types. It clearly tells the agent when to choose this tool over alternative approaches, though it does not name specific sibling tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation1/5

The server is named 'Phishtank' but only one tool (check_url) relates to phishing. The remaining 31 tools cover a wide range of unrelated topics (data research, prediction markets, memory, etc.), many with overlapping purposes (e.g., ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research). This makes it extremely difficult for an agent to select the right tool.

Naming Consistency2/5

Tool names mix conventions inconsistently: some use underscores (ai_visibility_check, check_url), some are camelCase (ask_pipeworx, bet_research), and others are compound phrases. There is no predictable pattern across the set.

Tool Count1/5

With 32 tools, the count is high, but only one aligns with the server name 'Phishtank' (check_url). The vast majority belong to an entirely different domain (Pipeworx tools), making the tool count severely inappropriate for the server's stated purpose.

Completeness1/5

For a phishing detection server, the tool surface is severely incomplete. It lacks essential tools like report_phish, verify_phish, get_stats, etc. The single phishing tool (check_url) is insufficient, while the other 31 tools are completely out of scope.